ArticleBMC infectious diseases2025
Development and validation of the AIDS scale among the system of quality of life instruments for chronic diseases (QLICD-HIV V2.0).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIn recent years, the prevalence of AIDS has shown a high increase, which has become a major public health problem of international concern. According to research, the quality of life(QoL) of AIDS patients is often lower than that of patients with other chronic diseases, so how to improve the QoL of AIDS patients has become a problem that needs to be urgently focused on at present. The purpose of this study is to develop and validate the AIDS scale among the System of Quality of Life Instruments for Chronic Diseases(QLICD), name as QLICD-HIV V2.0.
methodsQLICD-HIV V2.0 was developed using a programmed modular approach with multiple nominal and focus group discussions, in-depth interviews and quantitative statistical procedures. Pre-surveys and formal surveys were conducted on the preliminary version of the scale, thus completing the scale development and validation process. The reliability of the scale was analyzed using the correlation coefficient method, the variability method, and the Cronbach’s α coefficient method of classical test theory(CTT), the validity of the scale was analyzed using factor analysis and correlation analysis with the SF-36 as a criterion, and the responsiveness of the scale and of each domain/facet was assessed through paired t-tests of before and after admission scores, and calculation of the standardized response mean (SRM).
resultsQLICD-HIV V2.0 ultimately retained 43 items, resulting in a structure of 4 domains, subdivided into 12 facets. The scale was shown to have high reliability overall by several methods of CTT. The Cronbach’s α coefficient and test-retest reliability for the total scale were 0.90 and 0.88, respectively, with domain Cronbach’s α coefficient ranging from 0.74 to 0.85 and test-retest reliabilities ranging from 0.69 to 0.89. Factor analysis results showed KMO = 0.852, with three common factors extracted from 15 items of the specific module, accounting for 55.2% of the cumulative variance, and correlation and factor analyses confirmed good structural and criterion-related validity.
conclusionsQLICD-HIV V2.0 was developed in a systematic and scientific way, and showed good reliability and validity after preliminary application, which can be further promoted and used as a new QoL scale for AIDS patients with Chinese characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.